Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on Aclaris Therapeutis (NASDAQ: ACRS).The analyst commented, "Our KOLs like that ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)